2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03580616
(ClinicalTrials.gov)
October 24, 201826/6/2018Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa StudyAmyotrophic Lateral Sclerosis;Possible Amyotrophic SclerosisDrug: L-SerineElijah W. StommelBrain Chemistry Labs, Institute for EthnomedicineRecruiting18 YearsN/AAll50Phase 2United States
2NCT01835782
(ClinicalTrials.gov)
January 201327/3/2013Determining the Safety of L-serine in ALSDetermining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses.Amyotrophic Lateral Sclerosis (ALS)Drug: L-SerinePhoenix Neurological Associates, LTDInstitute for EthnomedicineActive, not recruiting18 Years85 YearsBoth20Phase 1;Phase 2United States